analogos glp 1 mecanismo de accion Existe un espacio para los análogos la incretina como terapia para el sobrepeso, la obesidad y la prevención de la enfermedad cardio-metabólica? Agonistas de GLP-1 más inhibidores

As more people start taking these medicines, I think we ENTs in India will see more of this

Using EHR data, Truveta Research explores prescribing patterns and patient characteristics for GLP-1 RA medications.

NRD per 1000 people 5.57 (6.61 to 4.53)), cannabis use (0.86 (0.81 to 0.90), NRD 2.25 (3.00 to 1.50)), cocaine use (0.80 (0.72 to 0.88), NRD 0.97 (1.37 to 0.57)), nicotine use (0.80 (0.74 to 0.87), NRD 1.64 (2.19 to 1.09)), and opioid use (0.75 (0.67 to 0.85), NRD 0.86 (1.19 to 0.52)), and other SUDs (0.87 (0.81 to 0.94), NRD 1.12 (1.68 to 0.55)) and composite outcome of all incident SUDs (0.86 (0.83 to 0.88), NRD 6.61 (7.95 to 5.26))

RCTs using dedicated retinal imaging are required to determine the causal relationship with these therapies

The findings are based on analysis of data from 2.4 million participants.

Experience convenient and reliable dosing with this 10-pack of 3 ml peptide cartridges, designed for compatibility with popular peptide pens and ideal for accurately administering medications like semaglutide and tirzepatide